FI953371A - TBE-virusinfektiota vastaan tähtäävään immunisointiin tarkoitetut parannetut rokotteet sekä menetelmä niiden valmistamiseksi - Google Patents

TBE-virusinfektiota vastaan tähtäävään immunisointiin tarkoitetut parannetut rokotteet sekä menetelmä niiden valmistamiseksi Download PDF

Info

Publication number
FI953371A
FI953371A FI953371A FI953371A FI953371A FI 953371 A FI953371 A FI 953371A FI 953371 A FI953371 A FI 953371A FI 953371 A FI953371 A FI 953371A FI 953371 A FI953371 A FI 953371A
Authority
FI
Finland
Prior art keywords
preparation
virus infection
immunization against
improved vaccines
tbe virus
Prior art date
Application number
FI953371A
Other languages
English (en)
Swedish (sv)
Other versions
FI953371A0 (fi
FI117974B (fi
Inventor
Franz Xaver Heinz
Steven Allison
Christian Mandl
Christian Kunz
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT0135294A external-priority patent/AT402897B/de
Priority claimed from AT0087195A external-priority patent/AT405607B/de
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of FI953371A0 publication Critical patent/FI953371A0/fi
Publication of FI953371A publication Critical patent/FI953371A/fi
Application granted granted Critical
Publication of FI117974B publication Critical patent/FI117974B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
FI953371A 1994-07-08 1995-07-07 Parannettu rokote immunisointiin TBE-virusinfektioita vastaan ja menetelmä sen valmistamiseksi FI117974B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AT0135294A AT402897B (de) 1994-07-08 1994-07-08 Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung
AT135294 1994-07-08
AT87195 1995-05-23
AT0087195A AT405607B (de) 1995-05-23 1995-05-23 Verbesserte vakzine zur immunisierung gegen tbe-virusinfektionen sowie ein verfahren zu dessen herstellung

Publications (3)

Publication Number Publication Date
FI953371A0 FI953371A0 (fi) 1995-07-07
FI953371A true FI953371A (fi) 1996-01-09
FI117974B FI117974B (fi) 2007-05-15

Family

ID=25594155

Family Applications (2)

Application Number Title Priority Date Filing Date
FI953371A FI117974B (fi) 1994-07-08 1995-07-07 Parannettu rokote immunisointiin TBE-virusinfektioita vastaan ja menetelmä sen valmistamiseksi
FI20070041A FI118222B (fi) 1994-07-08 2007-01-17 Parannettu rokote Flavivirusinfektioiden vastaiseen immunisointiin

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20070041A FI118222B (fi) 1994-07-08 2007-01-17 Parannettu rokote Flavivirusinfektioiden vastaiseen immunisointiin

Country Status (9)

Country Link
EP (2) EP0691404B1 (fi)
AT (2) ATE206459T1 (fi)
CZ (1) CZ282927B6 (fi)
DE (2) DE59508988D1 (fi)
DK (2) DK0691404T3 (fi)
ES (2) ES2165109T3 (fi)
FI (2) FI117974B (fi)
HU (2) HU219503B (fi)
RU (1) RU2150294C1 (fi)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6258788B1 (en) 1997-11-20 2001-07-10 The United States Of America As Represented By The Secretary Of The Army DNA vaccines against tick-borne flaviviruses
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
WO2003102166A2 (en) 2002-02-26 2003-12-11 Maxygen, Inc. Novel flavivirus antigens
WO2006067122A2 (en) 2004-12-20 2006-06-29 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
WO2006120230A2 (en) 2005-05-12 2006-11-16 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
CA2881717C (en) 2006-06-06 2018-06-12 Cecilia Anna Wilhelmina Geuijen Human binding molecules having killing activity against staphylococci and uses thereof
US8415361B2 (en) 2007-11-09 2013-04-09 The Salk Institute For Biological Studies Use of TAM receptor inhibitors as antimicrobials

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE122055T1 (de) * 1987-03-20 1995-05-15 Immuno Ag Dna- und rna-moleküle des westlichen subtyps des fsme-virus, polypeptide, die von diesen molekülen codiert werden, und deren verwendung.
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
WO1992003161A1 (en) 1990-08-27 1992-03-05 The United States Of America, Represented By The Secretary, United States Department Of Commerce Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection
DE69333814T2 (de) 1992-03-11 2006-02-02 Powderject Vaccines, Inc., Madison Genetischer impfstoff gegen den immunschwäche virus

Also Published As

Publication number Publication date
ATE206459T1 (de) 2001-10-15
CZ282927B6 (cs) 1997-11-12
CZ176995A3 (en) 1996-01-17
EP0869184A2 (de) 1998-10-07
EP0869184B1 (de) 2001-10-04
DK0869184T3 (da) 2001-12-17
HU219503B (hu) 2001-04-28
EP0869184A3 (de) 1999-05-12
EP0691404A3 (de) 1997-11-12
DE59509667D1 (de) 2001-11-08
ATE198909T1 (de) 2001-02-15
RU2150294C1 (ru) 2000-06-10
HU9903233D0 (en) 1999-11-29
ES2155510T3 (es) 2001-05-16
HUT72395A (en) 1996-04-29
FI953371A0 (fi) 1995-07-07
FI117974B (fi) 2007-05-15
FI20070041A (fi) 2007-01-17
EP0691404B1 (de) 2001-01-24
DE59508988D1 (de) 2001-03-01
EP0691404A2 (de) 1996-01-10
ES2165109T3 (es) 2002-03-01
HU224199B1 (hu) 2005-06-28
HU9501832D0 (en) 1995-08-28
FI118222B (fi) 2007-08-31
DK0691404T3 (da) 2001-03-19

Similar Documents

Publication Publication Date Title
DE69829668D1 (de) Herstellung und verwendung von rekombinanten influenza a virus m2 konstruktionen und impstoffe
ATE97164T1 (de) Rekombinantes vaccinia-virus mva.
DE3677494D1 (de) Virus-impfstoff.
SE9003978D0 (sv) Dna expressionssystem baserade paa ett virus replikon
CY1107570T1 (el) Ανοσογονικα πολυπεπτιδια κωδικοποιουμενα απο μινιγονιδια mage και οι χρησεις τους
PT101052A (pt) Proteinas hibridas uteis na preparacao de vacinas
CY1105600T1 (el) Κατασκευασματα νουκλεϊκων οξεων για γενετικη ανοσοποιηση
FI20070041A (fi) Parannettu rokote Flavivirusinfektioiden vastaiseen immuunisointiin
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
DK457687D0 (da) Antigenisk aktive proteiner og peptider, og vacciner mod virus for felin peritonitis (fipv) med indhold af saadanne proteiner eller peptider
FI885296A (fi) Rekombinant hiv-2 polypeptid.
EP0236977A3 (en) Bovine virus diarrhea and hog cholera vaccines
NL300336I2 (nl) Vaccin tegen de bof dat een jeryl-lynn virusstam bevat
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
WO1998052603A3 (en) An influenza enveloped dna vaccine
FR2724385B1 (fr) Vaccin de la peritonite infectieuse feline.
MX9301736A (es) Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1.

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117974

Country of ref document: FI

MM Patent lapsed